Name,SMILES,Halflife,Reference,Published Year of Data,Link,Mean,Geometric Mean,Harmonic Mean,Median,S.D.,Range,Review
Acamprosate,CC(=O)NCCCS(=O)(=O)O,5.7,FDA Approval Package Clinical Pharmacology and Biopharmaceutics Review 021431/S-000,2003,https://pharmapendium.com/browse/fda/Acamprosate%20Calcium/5b545aa5550c7d164648bed9de213184?reference=23,5.7 h,,,,2.8 h,,"From ""Basic"" table"
"Acetyl gitoxin, 16-",CC1C(C(CC(O1)OC2C(OC(CC2O)OC3C(OC(CC3O)OC4CCC5(C(C4)CCC6C5CCC7(C6(CC(C7C8=CC(=O)OC8)OC(=O)C)O)C)C)C)C)O)O,51.6,,,https://doi.org/10.1007/BF01059196,51.6 h,,,,,,
Alprazolam,Cc1nnc2CN=C(c3ccccc3)c3c(ccc(Cl)c3)-n12,16,FDA Approval Package Clinical Pharmacology and Biopharmaceutics Review 021434/S-000 Part 02,2001,https://pharmapendium.com/browse/fda/Alprazolam/5b1dbcc53585445affb218087ed14037?reference=40,16 h,,,,5.36 h,,"ABA group, No significance between groups accoring to ANOVA"
Alprostadil,CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O,0.133,FDA Approval Package Clinical Pharmacology and Biopharmaceutics Review 020649/S-000,1997,https://pharmapendium.com/browse/fda/Alprostadil/8b783fb996a9e03c7add1e39c829e4c9?reference=5,8 min,,,,,,
Alvimopan,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(=O)O)CC[C@@]1(C)c1cccc(O)c1,5.3,FDA Approval Package Clinical Pharmacology and Biopharmaceutics Review 021775/S-000,2005,https://pharmapendium.com/browse/fda/Alvimopan/53586f6e003678da3e6228504fc758f3?reference=80,5.3 h,4.2 h,,,3.8 h,,
Amifostine,NCCCNCCSP(=O)(O)O,0.133,FDA Approval Package 020221/S-002 Part 01,1995,https://pharmapendium.com/browse/fda/Amifostine/216b0bf97c3ef0eb32a8a5ff04987e6b?reference=26,,,,,,,β phase
"Aminocyclopropanecarboxylic acid, 1-",C1CC1(C(=O)O)N,5.9,,,https://doi.org/10.1002/jps.2600841016,,,,,,,
"Aminohexanoic acid, 6-",NCCCCCC(=O)O,4.9,"Frederiksen, M.C., Bowsher, D.J., Ruo, T.I., Henthorn, T.K., Ts'ao, C.-H., Green, D. and Atkinson, A.J., Jr (1984), Kinetics of epsilon-aminocaproic acid distribution, elimination, and antifibrinolytic effects in normal subjects. Clinical Pharmacology & Therapeutics, 35: 387-393.",1984,https://doi.org/10.1038/clpt.1984.48,4.9 h,,,,3.05 h,,
Amitriptyline,CN(C)CCC=C1c2ccccc2CCc2ccccc12,12.8,"Filser, J. G., Kaumeier, S., Brand, T., Schanz, H., Terlinden, R., & Müller, W. E. (1988). Pharmacokinetics of amitriptyline and amitriptylinoxide after intravenous or oral administration in humans. Pharmacopsychiatry, 21(06), 381-383.",1988,https://doi.org/10.1055/s-2007-1017018,,,,,,,
Amodiaquine,CCN(CC)Cc1cc(Nc2ccnc3c2ccc(Cl)c3)ccc1O,2.1,"White, N. J.; Looareesuwan, Sornchai; Edwards, G.; Phillips, R. E.; Karbwang, Juntra; Nicholl, Deborah D.; Bunch, C.; Warrell, D. A.. Pharmacokinetics of intravenous amodiaquine. British Journal of Clinical Pharmacology (1987), 23(2), 127-135",1987,https://doi.org/10.1111/j.1365-2125.1987.tb03020.x,,2.1 h,,,,0.5 h-5.7 h,Elimination phase
Bepridil,CC(C)COC[C@@H](CN(Cc1ccccc1)c1ccccc1)N1CCCC1,14.9,"Lawrence J. Lesko, Joseph R. Benotti, Joseph S. Alpert, Priscilla M. Brady, Jane E. McCue, Bonnie H. Weiner, Ira S. Ockene,
Pharmacokinetics of Intravenous Bepridil in Patients With Coronary Disease,
Journal of Pharmaceutical Sciences,
Volume 75, Issue 10,
1986,
Pages 952-954",1986,https://doi.org/10.1002/jps.2600751008,14.9 h,,,,,7.4 h-64 h,Model-independent analysis
Bimatoprost,CCNC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C\[C@@H](O)CCc1ccccc1,0.75,EMA Approval Package ANNEX I,2021,https://pharmapendium.com/browse/ema/Bimatoprost/19eb222ad4ec50b96c11114bbe8787c7?reference=8,45 min,,,,,,
Calcitriol,C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)(C)O)C[C@@H](O)C[C@@H]1O,25.9,"Lisbet Brandi, Martin Egfjord, Klaus Olgaard, Pharmacokinetics of 1,25(OH)2D3 and 1α(OH)D3 in normal and uraemic men, Nephrology Dialysis Transplantation, Volume 17, Issue 5, May 2002, Pages 829–842",2002,https://doi.org/10.1093/ndt/17.5.829,25.91 h,,,,3.48 h,,
Cefmenoxime,CO/N=C(\C(=O)N[C@H]1C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)CS[C@H]12)c1csc(N)n1,0.96,FDA Approval Package 050571 Part 01,1987,https://pharmapendium.com/browse/fda/Cefmenoxime%20Hydrochloride/d2aca4fcb286f5a4bc51c0e42c7c6d63?reference=44,0.96 h,,,,,,"Least dose, injection"
Cefonicid,O=C(O)C1=C(CSc2nnnn2CS(=O)(=O)O)CS[C@@H]2[C@@H](NC(=O)[C@H](O)c3ccccc3)C(=O)N12,5.24,"Fourtillan, J. B., Leroy, A., Lefebvre, M. A., Humbert, G., Fillastre, J. P., Reumont, G., & Ramis, N. (1985). Cross-over study of the pharmacokinetics of cefonicid administered intravenously or intramuscularly to healthy adult humans. European journal of drug metabolism and pharmacokinetics, 10(3), 225–230.",1985,https://doi.org/10.1007/BF03189746,5.24 h,,,,0.84 h,,"β phase, HPLC"
Cefotiam,CN(C)CCn1nnnc1SCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cc3csc(N)n3)[C@H]2SC1,0.767,FDA Approval Package 050601 Part 04,1988,https://pharmapendium.com/browse/fda/Cefotiam%20Hydrochloride/99b0aff8e2d4a4b376d82ac8facc76ac?reference=33,46 min,,,,,,Least dose
Cefpiramide,Cc1cc(=O)c(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSc4nnnn4C)CS[C@H]23)c2ccc(O)cc2)c[nH]1,5.41,"Conte J. E., Jr (1987). Pharmacokinetics of cefpiramide in volunteers with normal or impaired renal function. Antimicrobial agents and chemotherapy, 31(10), 1585–1588. ",1987,https://doi.org/10.1128/AAC.31.10.1585,5.41 h,,,,1.44 h,,
Cephacetrile,CC(=O)OCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)CC#N)[C@H]2SC1,2.02,"Domínguez-Gil, A., Castiñeiras, M.C., Tabernero, J.M. et al. Pharmacokinetics of cephacetrile in patients with normal or impaired renal function. Eur J Clin Pharmacol 13, 445–448 (1978)",1978,https://doi.org/10.1007/BF00566324,,,,,,,β phase
Chlorprothixene,CN(C)CC/C=C1/c2ccccc2Sc2ccc(Cl)cc12,25.8,"Bagli, M., Rao, M. L., Höflich, G., Kasper, S., Langer, M., Barlage, U., Beneke, M., Süverkrüp, R., & Möller, H. J. (1996). Pharmacokinetics of chlorprothixene after single intravenous and oral administration of three galenic preparations. Arzneimittel-Forschung, 46(3), 247–250.",1996,https://pubmed.ncbi.nlm.nih.gov/8901143/,25.8 h,,,,13.6 h,,
Cinacalcet,C[C@@H](NCCCc1cc(C(F)(F)F)ccc1)c1c2ccccc2ccc1,19.9,FDA Approval Package Pharmacology Review 021688/S-000 Part 01,2004,https://pharmapendium.com/browse/fda/Cinacalcet%20Hydrochloride/cdf0d09d4dacc43779019541b57a43ef?reference=28,,,,,,,
Clopidogrel,COC(=O)[C@H](c1ccccc1Cl)N1CCc2c(ccs2)C1,3.3,"Collet, JP., Funck-Brentano, C., Prats, J. et al. Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study. Am J Cardiovasc Drugs 16, 43–53 (2016).",2016,https://doi.org/10.1007/s40256-015-0145-0,3.30 h,,,,1.37 h,,Least dose
Danazol,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5c(cno5)C[C@]4(C)[C@H]3CC[C@@]21C,0.17,"Sunesen VH, Vedelsdal R, Kristensen HG, Christrup L, Müllertz A. Effect of liquid volume and food intake on the absolute bioavailability of danazol, a poorly soluble drug. Eur J Pharm Sci. 2005 24, 297-303.",2005,https://doi.org/10.1016/j.ejps.2004.11.005,2.2 h,,,,1.0 h,,
Daunorubicin,COc1c2C(=O)c3c(O)c4c(C[C@@](O)(C(C)=O)C[C@@H]4O[C@H]4C[C@H](N)[C@H](O)[C@H](C)O4)c(O)c3C(=O)c2ccc1,12.4,"Milena Locci de Oliveira, Adriana Rocha, Glauco Henrique Balthazar Nardotto, Leandro Francisco Pippa, Belinda Pinto Simões, Vera Lucia Lanchote,
Analysis of daunorubicin and its metabolite daunorubicinol in plasma and urine with application in the evaluation of total, renal and metabolic formation clearances in patients with acute myeloid leukemia,
Journal of Pharmaceutical and Biomedical Analysis,
Volume 191,
2020,
113576",2020,https://doi.org/10.1016/j.jpba.2020.113576,12.4 h,,,,,9.61 h-16 h,
"DCQA, 1,3-",C1[C@H]([C@H]([C@@H](C[C@@]1(C(=O)O)OC(=O)/C=C/C2=CC(=C(C=C2)O)O)OC(=O)/C=C/C3=CC(=C(C=C3)O)O)O)O  ,1.35,,,https://doi.org/10.1016/j.phymed.2014.11.014,1.35 h,,,,0.3 h,,
"DCQA, 3,4-",C1[C@H]([C@H]([C@@H](C[C@@]1(C(=O)O)O)OC(=O)/C=C/C2=CC(=C(C=C2)O)O)OC(=O)/C=C/C3=CC(=C(C=C3)O)O)O,1.95,,,https://doi.org/10.1016/j.phymed.2014.11.014,1.95 h,,,,0.3 h,,
"DCQA, 3,5-",C1C(C[C@H](C([C@@H]1OC(=O)/C=C/C2=CC(=C(C=C2)O)O)O)OC(=O)/C=C/C3=CC(=C(C=C3)O)O)(O)C(=O)O,4.15,,,https://doi.org/10.1016/j.phymed.2014.11.014,4.15 h,,,,3.85 h,,
"Demethylfortimicin A, 3-O-",C[C@@H]([C@@H]1CC[C@H]([C@H](O1)O[C@@H]2[C@H]([C@@H]([C@@H]([C@H]([C@H]2O)N(C)C(=O)CN)O)O)N)N)N,2.7,,,https://doi.org/10.1128/AAC.29.3.400,2.7 h,,,,,,
Desferrioxamine,CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN,3.05,"Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients.
P Lee, N Mohammed, L Marshall, R D Abeysinghe, R C Hider, J B Porter and S Singh
Drug Metabolism and Disposition July 1, 1993, 21 (4) 640-644",1993,https://dmd.aspetjournals.org/content/21/4/640,3.05 h,,,,1.3 h,,
Desipramine,CNCCCN1c2ccccc2CCc2ccccc21,22.4,"Ciraulo, D.A., Barnhill, J.G. and Jaffe, J.H. (1988), Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. Clinical Pharmacology & Therapeutics, 43: 509-518.",1988,https://doi.org/10.1038/clpt.1988.66,22.4 h,,,,4.91 h,,Control subjects
Dexamethasone m-Sulfobenzoate,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(=O)c1cc(S(=O)(=O)O)ccc1,5.4,"Hochhaus, G., Barth, J., Al-Fayoumi, S., Suarez, S., Derendorf, H., Hochhaus, R. and Möllmann, H. (2001), Pharmacokinetics and Pharmacodynamics of Dexamethasone Sodium-m-Sulfobenzoate (DS) after Intravenous and Intramuscular Administration: A Comparison with Dexamethasone Phosphate (DP). The Journal of Clinical Pharmacology, 41: 425-434.",2001,https://doi.org/10.1177/00912700122010285,5.4 h,,,,3.0 h,,"Itself, not dexamethasone"
Dezocine,C[C@@]12CCCCC[C@@H](Cc3ccc(O)cc31)[C@@H]2N,4.2,"Wilson, J.M., Cohen, R.I., Kezer, E.A., Schange, S.J. and Smith, E.R. (1995), Single- and Multiple-Dose Pharmacokinetics of Dezocine in Patients With Acute or Chronic Pain. The Journal of Clinical Pharmacology, 35: 398-403.",1995,https://doi.org/10.1002/j.1552-4604.1995.tb04080.x,4.2 h,,,,1.4 h,,"β phase, Table 1, minimum dose"
Diazepam,CN1C(=O)CN=C(c2ccccc2)c2c1ccc(Cl)c2,56.2,FDA Approval Package Summary Review 211635/S-000 Part 02,2020,PharmaPendium - FDA Approval Package - Diazepam > Summary Review > Summary Review 211635/S-000 Part 02,56.2 h,,,,21.0 h,,
Diclofenac,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,1.44,FDA Approval Package Label 022396/S-000,2014,https://pharmapendium.com/browse/fda/Diclofenac%20Sodium/114c3525b2b011e67e41865ee0e39f6e?reference=14,1.44 h,,,,0.27 h,,
Dihydroergotamine,CN1C[C@H](C(=O)N[C@]2(C)O[C@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3c4c(c[nH]c4ccc3)C[C@H]21,0.548,"Kanto, J., Allonen, H., Koski, K., Koulu, M., Lammintausta, R., Mäntylä, R., Kleimola, T., & Siirtola, T. (1981). Pharmacokinetics of dihydroergotamine in healthy volunteers and in neurological patients after a single intravenous injection. International journal of clinical pharmacology, therapy, and toxicology, 19(3), 127–130.",1981,https://pubmed.ncbi.nlm.nih.gov/7228454/,32.9 min,,,,,,β phase
Diltiazem,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1,3.75,FDA Approval Package Label 020092/S-016,2010,https://pharmapendium.com/browse/fda/Diltiazem%20Hydrochloride/9de29b9082976a5adcae970871981e39?reference=4,,,,,,3.0 h-4.5 h,Midpoint of range
Diphenhydramine,CN(C)CCOC(c1ccccc1)c1ccccc1,8.5,"Blyden, G. T., Greenblatt, D. J., Scavone, J. M., & Shader, R. I. (1986). Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration. Journal of clinical pharmacology, 26(7), 529–533.",1986,https://doi.org/10.1002/j.1552-4604.1986.tb02946.x,8.5 h,,,,1.0 h,,
Dipyridamole,OCCN(CCO)c1nc2c(nc(N(CCO)CCO)nc2N2CCCCC2)c(N2CCCCC2)n1,11.6,"Bjornsson TD, Mahony C. Clinical pharmacokinetics of dipyridamole. Thromb Res Suppl. 1983, 4, 93-104.",1983,https://doi.org/10.1016/0049-3848(83)90364-X,11.6 h,,,,2.2 h,,Terminal halflife of tri-exponential decline
"dOTC, (-)-",C1[C@@H](S[C@@H](O1)CO)N2C=CC(=NC2=O)N,8.92,,,https://doi.org/10.1128/AAC.44.6.1609-1615.2000,8.92 h,,,6.80 h,69.90%,,terminal 
"dOTC, (+)-",C1[C@H](S[C@H](O1)CO)N2C=CC(=NC2=O)N,19.2,,,https://doi.org/10.1128/AAC.44.6.1609-1615.2000,19.2 h,,,18.0 h,31.50%,,terminal 
Doxazosin,COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC,11,"FDA Approval Package 019668/S-001, S-002, S-003, S-004, S-007 Part 09",1990,https://pharmapendium.com/browse/fda/Doxazosin%20Mesylate/0fc529e89eff0880d2e07fe24bb85a1c?reference=14,,,,,,,
Droperidol,O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1,2.06,"Cooper, I., Landersdorfer, C. B., St John, A. G., & Graudins, A. (2018). The pharmacokinetics of intranasal droperidol in volunteers characterised via population modelling. SAGE open medicine, 6, 2050312118813283. ",2018,https://doi.org/10.1177/2050312118813283,,,,2.06 h,,1.87 h-2.15 h,
Enoximone,CSc1ccc(C(=O)c2c(C)[nH]c(=O)[nH]2)cc1,2.02,KOIKE. Pharmacokinetics of Enoximone after Various Intravenous Administrations to Healthy Volunteers.,1994,https://doi.org/10.1002/jps.2600840206,2.02 h,,,,0.83 h,,"β phase, least dose"
Erlotinib,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,7.07,"Ranson, M., Shaw, H., Wolf, J. et al. A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva®, OSI-774) in patients with advanced solid tumors of epithelial origin. Cancer Chemother Pharmacol 66, 53–58 (2010). https://doi.org/10.1007/s00280-009-1133-3",2009,https://doi.org/10.1007/s00280-009-1133-3,,,,7.07 h,,2.75 h-15.2 h,"For dosage of 25 mg IV administration is interrupted, apart from this, least dose of 50 mg is selected, non-compartmental terminal halflife"
Ethacrynic Acid,C=C(CC)C(=O)c1ccc(OCC(=O)O)c(Cl)c1Cl,0.497,"Lacreta FP, Brennan JM, Nash SL, Comis RL, Tew KD, and O'Dwyer P (1994) Pharmacokinetics and bioavailability study of ethacrynic acid as a modulator of drug resistance in patients with cancer.  J. Pharmacol. Exp. Ther. 270:  1186-1191.",1994,https://jpet.aspetjournals.org/content/270/3/1186.long,29.8 min,,,,,11.8 min-160 min,"Biphasic major, value pharmapendium search "
Etomidate,CCOC(=O)c1cncn1[C@H](C)c1ccccc1,4.6,FDA Approval Package 018228 Part 01,1982,https://pharmapendium.com/browse/fda/Etomidate/31b0fd123106d77e0564743ba72e3665?reference=75,4.6 h,,,,2.6 h,,
Fenoldopam,Oc1ccc([C@H]2CNCCc3c2cc(O)c(O)c3Cl)cc1,0.0833,FDA Approval Package Label 019922/S-005,2004,https://pharmapendium.com/browse/fda/Fenoldopam%20Mesylate/d7903ed35991bc2fa5ab094c1892cd3d?reference=2,5 min,,,,,,Little difference between R and S isomers
Fenoprofen,C[C@@H](C(=O)O)c1cc(Oc2ccccc2)ccc1,2.24,"Rubin, A., Rodda, B. E., Warrick, P., Ridolfo, A. S., & Gruber, C. M., Jr (1972). Physiological disposition of fenoprofen in man. II. Plasma and urine pharmacokinetics after oral and intravenous administration. Journal of pharmaceutical sciences, 61(5), 739–745.",1972,https://doi.org/10.1002/jps.2600610514,134.5 min,,,139 min,35.5min,87 min-173 min,Averaged of 4 subjects
Flunisolide,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1.6,"Chaplin, M. D., Rooks, W., 2nd, Swenson, E. W., Cooper, W. C., Nerenberg, C., & Chu, N. I. (1980). Flunisolide metabolism and dynamics of a metabolite. Clinical pharmacology and therapeutics, 27(3), 402–413.",1980,https://doi.org/10.1038/clpt.1980.54,1.6 h,,,,0.1 h,,
"Fluorouracil, 5-",O=c1[nH]cc(F)c(=O)[nH]1,0.241,"Port R, E, Daniel B, Ding R, W, Herrmann R: Relative Importance of Dose, Body Surface Area, Sex, and Age for 5-Fluorouracil Clearance. Oncology 1991;48:277-281",1991,https://doi.org/10.1159/000226942,14.5 min,,,14.5 min,2.7 min,10.7 min-17.1 min,Averaged in Table 1 Group 1c (no MTX and least frequency)
Flupenthixol,OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(C(F)(F)F)cc23)CC1,26.3,"Balant-Gorgia, A.E., Balant, L. Antipsychotic Drugs. Clin-Pharmacokinet 13, 65–90 (1987).",1987,https://doi.org/10.2165/00003088-198713020-00001,,,,,,,Averaged from 3 subjects' mean
Fluvoxamine,COCCCC/C(=N\OCCN)c1ccc(C(F)(F)F)cc1,12.9,"Orlando, R., De Martin, S., Andrighetto, L., Floreani, M. and Palatini, P. (2010), Fluvoxamine pharmacokinetics in healthy elderly subjects and elderly patients with chronic heart failure. British Journal of Clinical Pharmacology, 69: 279-286.",2010,https://doi.org/10.1111/j.1365-2125.2009.03587.x,12.9 h,,,,6.4 h,,Young subjects
Fosphenytoin,O=C1NC(c2ccccc2)(c2ccccc2)C(=O)N1COP(=O)(O)O,0.25,FDA Approval Package Clinical Pharmacology and Biopharmaceutics Review 020450/S-003 Part 01,2017,https://pharmapendium.com/browse/fda/Fosphenytoin%20Sodium/cc0b14ad2b9fb61feabdc12ce296d3f4?reference=5,15 min,,,,,,
Fusidic Acid,CC(=O)O[C@H]1C[C@@]2(C)[C@@H](C[C@@H](O)[C@H]3[C@]4(C)CC[C@@H](O)[C@@H](C)[C@@H]4CC[C@]32C)/C1=C(/CCC=C(C)C)C(=O)O,14.5,"Turnidge J. (1999). Fusidic acid pharmacology, pharmacokinetics and pharmacodynamics. International journal of antimicrobial agents, 12 Suppl 2, S23–S34. https://doi.org/10.1016/s0924-8579(98)00071-5",1999,https://doi.org/10.1016/s0924-8579(98)00071-5,,,,,,,"β phase, latest reference"
Gefitinib,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,40.3,EMA Approval Package Assessment Report EMEA/CHMP/563746/2008,2009,https://pharmapendium.com/browse/ema/Gefitinib/a48f233c70e055224aba1f9710c85c9e?reference=11,,,,,,,Least dose
Gemifloxacin,CO/N=C1\CN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3n2)CC1CN,8.69,"Kim, M.J., Lim, HS., Cho, SH. et al. Comparative Pharmacokinetics and Bioavailability of Gemifloxacin Administered as an Intravenous 200 mg Formulation or an Oral 320 mg Tablet. Clin Drug Investig 34, 195–201 (2014).",2014,https://doi.org/10.1007/s40261-013-0164-z,8.69 h,,,,2.20 h,,
Gliclazide,Cc1ccc(S(=O)(=O)NC(=O)NN2C[C@H]3CCC[C@@H]3C2)cc1,16.4,"Delrat, P., Paraire, M. and Jochemsen, R. (2002), Complete bioavailability and lack of food-effect on pharmacokinetics of gliclazide 30 mg modified release in healthy volunteers. Biopharm. Drug Dispos., 23: 151-157.",2002,https://doi.org/10.1002/bdd.303,16.4 h,,,,4.2 h,,
Grepafloxacin,Cc1c2c(=O)c(C(=O)O)cn(C3CC3)c2cc(N2CCN[C@H](C)C2)c1F,9.4,FDA Approval Package Clinical Pharmacology and Biopharmaceutics Review 020695,1997,https://pharmapendium.com/browse/fda/Grepafloxacin%20Hydrochloride/218aebf5bd41282ae21352e9185663f8?reference=13,9.4 h,,,,,,Least dose
Heroin,CC(=O)Oc1ccc2C[C@@H]3[C@@H]4C=C[C@H](OC(C)=O)[C@@H]5Oc1c2[C@@]54CCN3C,0.127,"Rook, E.J., Huitema, A.D.R., van den Brink, W. et al. Population Pharmacokinetics of Heroin and its Major Metabolites. Clin Pharmacokinet 45, 401–417 (2006)",2006,https://doi.org/10.2165/00003088-200645040-00005,7.6 min,,,,,,"Complex compartment model, estimated from intravenous + inhalation data"
Hexobarbital,CN1C(=O)NC(=O)C(C)(C2=CCCCC2)C1=O,4.35,"Breimer, D.D., Honhoff, C., Zilly, W. et al. Pharmacokinetics of hexobarbital in man after intravenous infusion. Journal of Pharmacokinetics and Biopharmaceutics 3, 1–11 (1975).",1975,https://doi.org/10.1007/BF01066591,261 min,,,,69 min,,
Ibuprofen,CC(C)Cc1ccc(C(C)C(=O)O)cc1,2.14,"Zhou, H., Xu, W., Wu, G., Wu, L., Shentu, J., Pan, Z., Hu, S., & Liu, Y. (2016). Pharmacokinetics and tolerability of intravenous ibuprofen injection in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study
. International journal of clinical pharmacology and therapeutics, 54(11), 904–913.",2016,https://doi.org/10.5414/CP202603,2.14 h,,,,0.34 h,,
Imipramine,CN(C)CCCN1c2ccccc2CCc2ccccc21,19.9,"Ciraulo, D.A., Barnhill, J.G. and Jaffe, J.H. (1988), Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. Clinical Pharmacology & Therapeutics, 43: 509-518.",1988,https://doi.org/10.1038/clpt.1988.66,19.9 h,,,,4.99 h,,Control subjects
Ketamine,CNC1(c2ccccc2Cl)CCCCC1=O,1.04,"Xie, H., Wang, X., Liu, G., & Wang, G. (2003). Analgesic effects and pharmacokinetics of a low dose of ketamine preoperatively administered epidurally or intravenously. The Clinical journal of pain, 19(5), 317-322.",2003,https://doi.org/10.1097/00002508-200309000-00006,62.54 min,,,,14.93 min,,
Levetiracetam,CC[C@@H](C(N)=O)N1CCCC1=O,7.13,"Toublanc, N., Du, X., Liu, Y. et al. Pharmacokinetics, Safety and Bioequivalence of Levetiracetam Intravenous Infusion and Oral Tablets in Healthy Chinese Subjects. Clin Drug Investig 35, 495–503 (2015). ",2015,https://doi.org/10.1007/s40261-015-0303-9,,7.13 h,,,,,Healthy Chinese
Lorcainide,CC(C)N1CCC(N(C(=O)Cc2ccccc2)c2ccc(Cl)cc2)CC1,7.8,"Keefe, D. L. (1984). Pharmacology of lorcainide. The American Journal of Cardiology, 54(4), 18-21.",1984,https://doi.org/10.1016/0002-9149(84)90819-1,7.8 h,,,,,5 h-12 h,
Mannitol,OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,4.5,EMA Approval Package Assessment Report EMA/CHMP/121817/2012,2012,https://pharmapendium.com/browse/ema/Mannitol/92e8f2a00e99749b6cd00ba210c5c345?reference=25,4.5 h,,,,1.1 h,,
Maraviroc,Cc1nnc(C(C)C)n1C1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,13.2,EMA Approval Package ANNEX I,2020,https://pharmapendium.com/browse/ema/Maraviroc/c4b566d7660838911f6e544f697ed177?reference=24,,,,,,,
Melatonin,COc1cc2c(cc1)[nH]cc2CCNC(C)=O,0.657,"Andersen, L. P., Werner, M. U., Rosenkilde, M. M., Harpsøe, N. G., Fuglsang, H., Rosenberg, J., & Gögenur, I. (2016). Pharmacokinetics of oral and intravenous melatonin in healthy volunteers. BMC pharmacology & toxicology, 17, 8. ",2016,https://doi.org/10.1186/s40360-016-0052-2,39.4 min,,,,3.6 min,,
Methoxsalen,COc1c2oc(=O)ccc2cc2c1occ2,0.63,"Berezhkovskiy L. M. (2013). Prediction of drug terminal half-life and terminal volume of distribution after intravenous dosing based on drug clearance, steady-state volume of distribution, and physiological parameters of the body. Journal of pharmaceutical sciences, 102(2), 761–771.",2013,https://doi.org/10.1002/jps.23396,,,,,,,
Methylergonovine,CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3c4c(c[nH]c4ccc3)C[C@H]2N(C)C1,3.39,FDA Approval Package 006035/S-078 Part 01,2012,https://pharmapendium.com/browse/fda/Methylergonovine%20Maleate/775921fa8318ab0bf05113ccdfc2a35e?reference=11,3.39 h,,,,,1.5 h-12.7 h,"Biphasic, terminal halflife"
Methylphenidate,COC(=O)C(c1ccccc1)C1CCCCN1,4.79,"Srinivas, N.R., Hubbard, J.W., Korchinski, E.D. et al. Enantioselective Pharmacokinetics of dl-threo-Methylphenidate in Humans. Pharm Res 10, 14–21 (1993). ",1993,https://doi.org/10.1023/A:1018956526016,,,,,,,Averaged of d and l isomer
Mianserin,CN1CCN2c3c(cccc3)Cc3ccccc3[C@H]2C1,9.6,"Shami, M., Elliott, H. L., Kelman, A. W., & Whiting, B. (1983). The pharmacokinetics of mianserin. British journal of clinical pharmacology, 15 Suppl 2(Suppl 2), 313S–322S. ",1983,https://doi.org/10.1111/j.1365-2125.1983.tb05880.x,9.6 h,,,,1.9 h,,Young subject
Midazolam,Cc1ncc2CN=C(c3ccccc3F)c3c(ccc(Cl)c3)-n21,3.8,"Lee, S., Lee, Y., Kim, A. H., Yoon, S., Lee, J., Ji, S. C., Yoon, S. H., Lee, S., Yu, K. S., Jang, I. J., & Cho, J. Y. (2021). Urinary metabolic markers reflect on hepatic, not intestinal, CYP3A activity in healthy subjects. Drug metabolism and pharmacokinetics, 36, 100374.",2021,https://doi.org/10.1016/j.dmpk.2020.12.001,3.80 h,,,,0.95 h,,
Midodrine,COc1cc([C@H](O)CNC(=O)CN)c(OC)cc1,0.417,FDA Approval Package Clinical Pharmacology and Biopharmaceutics Review 019815,1996,https://pharmapendium.com/browse/fda/Midodrine%20Hydrochloride/b93f41c6b2ff4230a9ec01475fb7d1f2?reference=33,25 min,,,,,,
Mifepristone,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,16.7,FDA Approval Package Clinical Pharmacology and Biopharmaceutics Review 020687/S-000 Part 02,1996,https://pharmapendium.com/browse/fda/Mifepristone/2c618771a1921cc9c07b97064c2be93e?reference=19,16.7 h,,,,1.6 h,,
Milnacipran,CCN(CC)C(=O)[C@]1(c2ccccc2)C[C@@H]1CN,6.4,FDA Approval Package Clinical Pharmacology and Biopharmaceutics Review 022256/S-000 Part 01,2008,https://pharmapendium.com/browse/fda/Milnacipran%20Hydrochloride/eee63f887193905c94dbc598c4037961?reference=79,6.4 h,,,,1.7 h,,
Mitotane,Clc1ccc(C(c2ccccc2Cl)C(Cl)Cl)cc1,2120,EMA Approval Package ANNEX I,2021,https://pharmapendium.com/browse/ema/Mitotane/3a436077eb206305d6cc8f06385fb60a?reference=10,,,,,,18 d-159 d,Midpoint of range
Moexipril,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2c(cc(OC)c(OC)c2)C[C@H]1C(=O)O,1.33,FDA Approval Package Clinical Pharmacology and Biopharmaceutics Review 020312 Part 01,1994,https://pharmapendium.com/browse/fda/Moexipril%20Hydrochloride/5ee0312b982e16f7ee0f7f10b94fbf51?reference=6,1.33 h,,,,0.32 h,,
Naltrexone,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,2.68,FDA Approval Package Pharmacology Review 021897/S-000 Part 01,2006,https://pharmapendium.com/browse/fda/Naltrexone/16d44222a5c486e4cbfb41cd47f886a2?reference=34,,,161 min,,,,
Naproxen,COc1cc2ccc([C@H](C)C(=O)O)cc2cc1,16.5,"M.V. Calvo, J.M. Lanao, A. Domínguez-Gil,
Bioavailability of rectally administered naproxen,
International Journal of Pharmaceutics,
Volume 38, Issues 1–3,
1987,
Pages 117-122",1987,https://doi.org/10.1016/0378-5173(87)90106-2,16.45 h,,,,3.12 h,,
Nedocromil,CCCc1c2c(cc3c1oc(C(=O)O)cc3=O)c(=O)cc(C(=O)O)n2CC,0.527,FDA Approval Package Clinical Pharmacology and Biopharmaceutics Review 020750,1997,https://pharmapendium.com/browse/fda/Nedocromil%20Sodium/a7413dab0a23e5ea7b833bc30746acbe?reference=1,31.6 min,,,,7.6 min,,
Nimodipine,COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c1cc([N+](=O)[O-])ccc1,1.2,"Langley, M.S., Sorkin, E.M. Nimodipine. Drugs 37, 669–699 (1989). https://doi.org/10.2165/00003495-198937050-00004",1989,https://doi.org/10.2165/00003495-198937050-00004,,,,,,0.9 h-1.5 h,Midpoint of range
Nitroglycerin,O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-],0.0833,FDA Approval Package Label 021780/S-000,2006,https://pharmapendium.com/browse/fda/Nitroglycerin/b405d7bd95a3851f1823f8d8fa065231?reference=5,5 min,,,,,,β phase
Norfloxacin,CCn1cc(C(=O)O)c(=O)c2c1cc(N1CCNCC1)c(F)c2,4.45,"陈西敬,柳晓泉,黄圣凯,王凤臣.诺氟沙星在健康人中的药代动力学[J].中国临床药理学杂志,1992(02):82-86",1992,https://doi.org/10.13699/j.cnki.1001-6821.1992.02.005,4.45 h,,,,1.42 h,,
Orciprenaline,CC(C)NCC(O)c1cc(O)cc(O)c1,6,"Dengler, H. G., & Hengstmann, J. H. (1976). Metabolism and pharmacokinetics of orciprenaline in various animal species and man. Archives internationales de pharmacodynamie et de therapie, 223(1), 71–87.",1976,https://pubmed.ncbi.nlm.nih.gov/999404/,,,,,,,Slower phase
Oxprenolol,C=CCOc1c(OC[C@H](O)CNC(C)C)cccc1,1.09,"Bradbrook, I. D., John, V. A., Morrison, P. J., Rogers, H. J., & Spector, R. G. (1985). Pharmacokinetic investigation of the absorption of oxprenolol from Oros delivery systems in healthy volunteers: comparison of in vivo and in vitro drug release. British journal of clinical pharmacology, 19 Suppl 2(Suppl 2), 163S–169S. ",1985,https://doi.org/10.1111/j.1365-2125.1985.tb02757.x,1.09 h,,,,0.24 h,,
Paliperidone,Cc1c(CCN2CCC(c3noc4cc(F)ccc34)CC2)c(=O)n2CCCC(O)c2n1,24.6,FDA Approval Package Clinical Pharmacology and Biopharmaceutics Review 021999/S-000 Part 02,2006,https://pharmapendium.com/browse/fda/Paliperidone/755396c081b9fd837bad4f83eed1511b?reference=10,24.6 h,,,,4.8 h,,
Pengitoxin,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3CC[C@]5([C@@]4(C[C@@H]([C@@H]5C6=CC(=O)OC6)OC(=O)C)O)C)C)OC(=O)C)O[C@H]7C[C@@H]([C@@H]([C@H](O7)C)O[C@H]8C[C@@H]([C@@H]([C@H](O8)C)OC(=O)C)OC(=O)C)OC(=O)C,60.8,,,https://doi.org/10.1007/BF01059196,60.8 h,,,,,,
"Penicillamine, D-",CC(C)(S)[C@@H](N)C(=O)O,1.05,"Wiesner, R. H., Dickson, E. R., Carlson, G. L., McPhaul, L. W., & Go, V. L. (1981). The pharmacokinetics of D-penicillamine in man. The Journal of rheumatology. Supplement, 7, 51–55.",1981,https://pubmed.ncbi.nlm.nih.gov/6939886/,62.7 min,,,,5.3 min,,
Phentolamine,Cc1ccc(N(CC2=NCCN2)c2cc(O)ccc2)cc1,2.4,FDA Approval Package Clinical Pharmacology and Biopharmaceutics Review 022159/S-000,2007,https://pharmapendium.com/browse/fda/Phentolamine%20Mesylate/7d517fc2627916ba1b5645cb27d1f701?reference=21,2 h 24 min,,,,38 min,,Treatment B
Phenytoin,O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1,14.57,"Karol, M.D., Locke, C.S. and Cavanaugh, J.H. (1999), Lack of Pharmacokinetic Interaction between Lansoprazole and Intravenously Administered Phenytoin. The Journal of Clinical Pharmacology, 39: 1283-1289.",1999,https://doi.org/10.1177/00912709922011971,14.57 h,,,,6.18 h,,With placebo
Piretanide,NS(=O)(=O)c1cc(C(=O)O)cc(N2CCCC2)c1Oc1ccccc1,1.29,"Trenk D, Wagner F, Jähnchen E, Spahn H, Mutschler E. Pharmacokinetics and bioavailability of piretanide in healthy volunteers following intramuscular administration. Arzneimittel-forschung. 1987 Dec;37(12):1382-1385.",1987,https://pubmed.ncbi.nlm.nih.gov/3449067/,1.29 h,,,,0.40 h,,
Posaconazole,CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6c(F)cc(F)cc6)C5)cc4)CC3)cc2)c1=O,18.7,"Kersemaekers, W. M., van Iersel, T., Nassander, U., O'Mara, E., Waskin, H., Caceres, M., & van Iersel, M. L. (2015). Pharmacokinetics and safety study of posaconazole intravenous solution administered peripherally to healthy subjects. Antimicrobial agents and chemotherapy, 59(2), 1246–1251.",2015,https://doi.org/10.1128/AAC.04223-14,18.7 h,,,,34%,,Least dose
Pramipexole,CCCN[C@H]1CCc2c(C1)sc(N)n2,12.6,FDA Approval Package 020667/S-000,1997,https://pharmapendium.com/browse/fda/Pramipexole%20Dihydrochloride/19c35dae583648e93194933ce335d701?reference=682,12.6 h,,,,,,λ phase
Prednisone,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,2.99,"Rose, J.Q., Yurchak, A.M. & Jusko, W.J. Dose dependent pharmacokinetics of prednisone and prednisolone in man. Journal of Pharmacokinetics and Biopharmaceutics 9, 389–417 (1981).",1981,https://doi.org/10.1007/BF01060885,2.99 h,,,,2.08 h,,Least dose
Promethazine,CC(CN1c2ccccc2Sc2ccccc21)N(C)C,12.2,"Taylor, G., Houston, J., Shaffer, J. and Mawer, G. (1983), Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man.. British Journal of Clinical Pharmacology, 15: 287-293.",1983,https://doi.org/10.1111/j.1365-2125.1983.tb01501.x,12.2 h,,,,2.19 h,,
Quinidine,C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1c2cc(OC)ccc2ncc1,10.2,"Darbar, D., Dell'Orto, S., Mörike, K., Wilkinson, G.R. and Roden, D.M. (1997), Dietary salt increases first-pass elimination of oral quinidine. Clinical Pharmacology & Therapeutics, 61: 292-300.",1997,https://doi.org/10.1016/S0009-9236(97)90161-2,10.2 h,,,,1.6 h,,Low-salt diet
Raloxifene,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2c1ccc(O)c2,12.1,FDA Approval Package Clinical Pharmacology and Biopharmaceutics Review 020815/S-000,1997,https://pharmapendium.com/browse/fda/Raloxifene%20Hydrochloride/1008afaa8dd29e30c83a695e890e39b6?reference=14,,,12.1 h,,,,
Ramelteon,CCC(=O)NCC[C@@H]1CCc2ccc3OCCc3c21,1.8,EMA Approval Package Withdrawal Public Statement EMEA/CHMP/551287/2008,2008,https://pharmapendium.com/browse/ema/Ramelteon/5841c3e44aad8adfee1364233eb892ad?reference=10,,,,,,,
Ranolazine,COc1c(OC[C@H](O)CN2CCN(CC(=O)Nc3c(C)cccc3C)CC2)cccc1,1.65,"Jerling, M. Clinical Pharmacokinetics of Ranolazine. Clin Pharmacokinet 45, 469–491 (2006).",2006,https://doi.org/10.2165/00003088-200645050-00003,,,,,,1.4 h-1.9 h,Midpoint of range
Repaglinide,CCOc1c(C(=O)O)ccc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)c1,0.87,"Hatorp, V., Oliver, S., & Su, C. A. (1998). Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers. International journal of clinical pharmacology and therapeutics, 36(12), 636–641.",1998,"Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers - PubMed (nih.gov)",0.87 h,,,,,0.36 h-2.93 h,From pharmapendium search
Rofecoxib,CS(=O)(=O)c1ccc(C2=C(c3ccccc3)C(=O)OC2)cc1,9.9,FDA Approval Package Clinical Pharmacology and Biopharmaceutics Review 021042/S-000; 021052/S-000 Part 10,1998,https://pharmapendium.com/browse/fda/Rofecoxib/95e6f2b929e6a156636e2b1775d23699?reference=4,,,9.9 h,,,,
Scutellarin,C1=CC(=CC=C1C2=CC(=O)C3=C(C(=C(C=C3O2)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)O)O)O,1.3,,,https://doi.org/10.1016/j.phymed.2014.11.014,1.3 h,,,,0.5 h,,male-female mean
Sildenafil,CCCc1nn(C)c2c1nc(-c1c(OCC)ccc(S(=O)(=O)N3CCN(C)CC3)c1)[nH]c2=O,2.18,"Muirhead, G. J., Rance, D. J., Walker, D. K., & Wastall, P. (2002). Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil. British journal of clinical pharmacology, 53 Suppl 1(Suppl 1), 13S–20S.",2002,https://doi.org/10.1046/j.06-5251.2001.00028.x,,,2.18 h,,,,
Spirapril,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(=O)O)SCCS2,41,FDA Approval Package Clinical Pharmacology and Biopharmaceutics Review 020240 Part 01,1993,https://pharmapendium.com/browse/fda/Spirapril%20Hydrochloride/352382e110c78494a1a1d6bb9c1771e4?reference=29,41 h,,,,14 h,,β phase
Sulpiride,CCN1CCC[C@@H]1CNC(=O)c1c(OC)ccc(S(N)(=O)=O)c1,6.47,"Brès, J., & Bressolle, F. (1991). Pharmacokinetics of sulpiride in humans after intravenous and intramuscular administrations. Journal of pharmaceutical sciences, 80(12), 1119–1124.",1991,https://doi.org/10.1002/jps.2600801206,6.47 h,,,,1 h,,
Tazarotene,CCOC(=O)c1cnc(C#Cc2cc3c(cc2)SCCC3(C)C)cc1,6.2,"Tang-Liu, D.DS., Matsumoto, R.M. & Usansky, J.I. Clinical Pharmacokinetics and Drug Metabolism of Tazarotene. Clin Pharmacokinet 37, 273–287 (1999)",1999,https://doi.org/10.2165/00003088-199937040-00001,,,,,,,
Tenidap,NC(=O)n1c(O)c(C(=O)c2cccs2)c2c1ccc(Cl)c2,22.7,"Gardner, M., Wilner, K., Hansen, R., Fouda, H. and McMahon, G. (1995), Single and multiple dose pharmacokinetics of tenidap sodium in healthy subjects.. British Journal of Clinical Pharmacology, 39: 11S-15S.",1995,https://doi.org/10.1111/j.1365-2125.1995.tb04495.x,,,,,,,Day 1
Tenoxicam,CN1C(C(=O)Nc2ccccn2)=C(O)c2c(ccs2)S1(=O)=O,67,"Nilsen, O.G. Clinical Pharmacokinetics of Tenoxicam. Clin. Pharmacokinet. 26, 16–43 (1994).",1994,https://doi.org/10.2165/00003088-199426010-00003,67 h,,,,20 h,,Newest ref.
Tolbutamide,CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1,6.9,"Tremaine, L.M., Wilner, K.D. & Preskorn, S.H. A Study of the Potential Effect of Sertraline on the Pharmacokinetics and Protein Binding of Tolbutamide. Clin-Pharmacokinet 32, 31–36 (1997). ",1997,https://doi.org/10.2165/00003088-199700321-00005,,,6.9 h,,,,Day 1
Topiramate,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1,42.3,"Clark, A.M., Kriel, R.L., Leppik, I.E., Marino, S.E., Mishra, U., Brundage, R.C. and Cloyd, J.C. (2013), Intravenous topiramate: Comparison of pharmacokinetics and safety with the oral formulation in healthy volunteers. Epilepsia, 54: 1099-1105",2013,https://doi.org/10.1111/epi.12134,42.3 h,,,,6.2 h,,
Trandolapril,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@H]2CCCC[C@@H]21,0.26,FDA Approval Package 020528/S-001 Part 03,1996,https://pharmapendium.com/browse/fda/Trandolapril/2bbb5f8216c88886021f39d86ec079aa?reference=60,0.26 h,,,,0.02 h,,
Treprostinil,CCCCC[C@@H](O)CC[C@@H]1[C@@H](O)C[C@H]2Cc3c(cccc3OCC(=O)O)C[C@@H]12,0.7,FDA Approval Package Medical/Clinical Review 022387/S-000,2009,https://pharmapendium.com/browse/fda/Treprostinil%20Sodium/88c65b7851ca298b82c1c608b8c5087f?reference=96,0.7 h,,,,0.43 h,,Treatment A
Valdecoxib,Cc1c(-c2ccc(S(N)(=O)=O)cc2)c(-c2ccccc2)no1,7.41,FDA Approval Package Clinical Pharmacology and Biopharmaceutics Review 021341/S-000 Part 02,2001,https://pharmapendium.com/browse/fda/Valdecoxib/94ab11e29dad8a2b50d6701728624f4a?reference=2,7.41 h,,,,31%,,
"Verapamil, (-)-",COc1c(OC)cc(CCN(C)CCC[C@](C#N)(c2cc(OC)c(OC)cc2)C(C)C)cc1,4.81,"Eichelbaum, M., Mikus, G., & Vogelgesang, B. (1984). Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration. British journal of clinical pharmacology, 17(4), 453–458. ",1984,https://doi.org/10.1111/j.1365-2125.1984.tb02371.x,,,4.81 h,,,,
"Verapamil, (+)-",COc1c(OC)cc(CCN(C)CCC[C@@](C#N)(c2cc(OC)c(OC)cc2)C(C)C)cc1,4.08,"Eichelbaum, M., Mikus, G., & Vogelgesang, B. (1984). Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration. British journal of clinical pharmacology, 17(4), 453–458. ",1984,https://doi.org/10.1111/j.1365-2125.1984.tb02371.x,,,4.08 h,,,,
Warfarin,CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,36.4,"Andreasen, Per Buch, Vesell, Elliot S., (1974), Comparison of plasma levels of antipyrine, tolbutamide, and warfarin after oral and intravenous administration, Clinical Pharmacology & Therapeutics, 16",1974,https://doi.org/10.1002/cpt19741661059,36.4 h,,,,6.0 h,,
Yohimbine,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]21,1.52,"Pascal Le Corre, Gilles Dollo, François Chevanne, Roger Le Verge,
Biopharmaceutics and metabolism of yohimbine in humans,
European Journal of Pharmaceutical Sciences,
Volume 9, Issue 1,
1999,
Pages 79-84",1999,https://doi.org/10.1016/S0928-0987(99)00046-9,91.0 min,,,,33.6 min,,β phase
Zimelidine,CN(C)C/C=C(\c1ccc(Br)cc1)c1cccnc1,5.1,"Love, B.L., Moore, R.G., Thomas, J. et al. Pharmacokinetics of zimelidine in humans — Plasma levels and urinary excretion of zimelidine and norzimelidine after intravenous and oral administration of zimelidine. Eur J Clin Pharmacol 20, 135–139 (1981).",1981,https://doi.org/10.1007/BF00607150,5.1 h,,,,0.7 h,,
Zolpidem,Cc1ccc(-c2c(CC(=O)N(C)C)n3cc(C)ccc3n2)cc1,2.56,"Weinling, E., McDougall, S., Andre, F., Bianchetti, G. and Dubruc, C. (2006), Pharmacokinetic profile of a new modified release formulation of zolpidem designed to improve sleep maintenance. Fundamental & Clinical Pharmacology, 20: 397-403.",2006,https://doi.org/10.1111/j.1472-8206.2006.00415.x,2.56 h,,,,24%,,
Tolterodine,CC1=CC(=C(C=C1)O)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2,2.7,,,https://www.pharmapendium.com/browse/fda/Tolterodine%20Tartrate/6e332f6a5d3dbe94ce4228bc67cba26d?reference=8,2.7 h,,,,1.3 h,,1.28 mg dose
852A,CCC1=NC2=C(N1CCCCNS(=O)(=O)C)C3=CC=CC=C3N=C2N,7.17,,,https://doi.org/10.1177/0091270007303766,7.17 h,,,,2.25 h,,
Abacavir,C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)[C@@H]4C[C@@H](C=C4)CO,1.5,,,https://doi.org/10.2165/00003088-200847060-00001,1.5 h,,,,,,
Abanoquil,COC1=C(C=C2CN(CCC2=C1)C3=NC4=CC(=C(C=C4C(=C3)N)OC)OC)OC,5.9,,,https://doi.org/10.1111/j.1365-2125.1991.tb03959.x,5.9 h,,,,1.4 h,,
Abexinostat,CN(C)CC1=C(OC2=CC=CC=C21)C(=O)NCCOC3=CC=C(C=C3)C(=O)NO,5.9,,,https://doi.org/10.1200/jco.2008.26.15_suppl.14514,,,,,16.50%,,
